Genital Herpes News and Research RSS Feed - Genital Herpes News and Research

ZOTEN nanoparticles can help develop natural immunity against genital herpes

ZOTEN nanoparticles can help develop natural immunity against genital herpes

An effective vaccine against the virus that causes genital herpes has evaded researchers for decades. But now, researchers from the University of Illinois at Chicago working with scientists from Germany have shown that zinc-oxide nanoparticles shaped like jacks can prevent the virus from entering cells, and help natural immunity to develop. [More]
New study suggests that Neanderthals across Europe may have diseases carried out of Africa

New study suggests that Neanderthals across Europe may have diseases carried out of Africa

A new study suggests that Neanderthals across Europe may well have been infected with diseases carried out of Africa by waves of anatomically modern humans, or Homo sapiens. As both were species of hominin, it would have been easier for pathogens to jump populations, say researchers. This might have contributed to the demise of Neanderthals. [More]
Use of OTC medication not always a smart decision for yeast infection

Use of OTC medication not always a smart decision for yeast infection

Itching, burning, redness—a yeast infection can be a total pain. While they aren't life-threatening, yeast infections are irritating—both physically and mentally. So, when undesirable symptoms appear 'down there,' should you consult your physician or self diagnose and treat with over-the-counter medications? [More]
Study shows several Envigo rat models susceptible to genital HSV-2 infection

Study shows several Envigo rat models susceptible to genital HSV-2 infection

A scientific collaboration between Envigo and the Department of Infectious Disease at the University of Gothenburg, Sweden has unveiled study findings into rat models and their susceptibility to intra-vaginal herpes simplex virus-2 (HSV-2) infection. [More]
Over 3.7 billion people under 50 have genital HSV-1 infection, shows WHO report

Over 3.7 billion people under 50 have genital HSV-1 infection, shows WHO report

More than 3.7 billion people under the age of 50 – or 67% of the population – are infected with herpes simplex virus type 1 (HSV-1), according to the World Health Organization’s first global estimates of HSV-1 infection published today in the journal PLOS ONE. [More]
Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study. [More]
Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay. [More]
Vaginal silicone ring may protect women against HIV, herpes virus

Vaginal silicone ring may protect women against HIV, herpes virus

Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC). [More]
Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler. [More]
NanoViricides speeds up HerpeCide drug development program

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program. [More]
Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings from a pair of new studies could speed up the development of a universally accurate diagnostic test for human herpes simplex viruses, according to researchers at Johns Hopkins and Harvard universities and the National Institutes of Health. [More]
GBD analysis shows over 95% of global population has health problems

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet. [More]
Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory. [More]
Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea reports positive results from GEN-003 Phase 2 clinical trial for treatment of genital herpes

Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. [More]
Men undergoing circumcision may be at increased risk of infecting female partners with HIV

Men undergoing circumcision may be at increased risk of infecting female partners with HIV

In the midst of an international campaign to slow the spread of HIV in sub-Saharan Africa, the World Health Organization recommends male circumcision (the surgical removal of foreskin from the penis) which reduces HIV acquisition by 50-60%. [More]
NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection. [More]
Common herpes drug Valacyclovir decreases HIV-1 levels

Common herpes drug Valacyclovir decreases HIV-1 levels

Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes. [More]
Scientists design a promising vaccine for herpes viruses

Scientists design a promising vaccine for herpes viruses

Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine. [More]
New type of vaccine holds promise for prevention of genital herpes

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide. [More]
SLU investigators find promising candidates for new herpes virus treatments

SLU investigators find promising candidates for new herpes virus treatments

Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments. [More]
Advertisement
Advertisement